ALN-CIDEB / Alnylam, Regeneron - LARVOL DELTA

Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals

New P2 trial • Fibrosis • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) (clinicaltrials.gov) - P1/2 | N=132 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Phase classification: P1 ➔ P1/2

Phase classification • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) (clinicaltrials.gov) - P1 | N=132 | Recruiting | Sponsor: Regeneron Pharmaceuticals | N=100 ➔ 132

Enrollment change • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease